European Association for the Study of the Liver. Electronic address: easloffice@easloffice.euClinical Practice Guideline Panel: Chair:Panel membersEASL Governing Board representative:2025-01-072025-01-072019-03-27https://hdl.handle.net/10668/25871Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.enAdultAgedChemical and Drug Induced Liver InjuryFatty LiverFemaleHistocompatibility TestingHumansLiver NeoplasmsMaleMiddle AgedMitochondriaPractice Guidelines as TopicRisk Factorsresearch article30926241open access10.1016/j.jhep.2019.02.0141600-0641http://www.journal-of-hepatology.eu/article/S0168827819301291/pdf